Laboratório de Biotecnologia Infecto-Parasitária, Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Campus Universitário s/n, Prédio 19-, Pelotas, RS, 96010-900, Brazil.
Laboratório de Biotecnologia Aplicada a Doenças Infecto-Parasitárias, Centro de Ciências Biológicas e da Saúde, Universidade Federal Rural do Semiárido, Mossoró, Brazil.
Appl Microbiol Biotechnol. 2021 Mar;105(6):2287-2296. doi: 10.1007/s00253-021-11191-4. Epub 2021 Mar 2.
Caseous lymphadenitis (CLA) is an infectious chronic disease responsible for economic losses in sheep and goat breeding worldwide. CLA has no effective treatment, evidencing the vaccination schedule as the best control strategy. Although some commercial vaccines have been available, none of them provides total protection, which is sometimes insufficient and does not reach the same efficiency when compared in sheep and goats. They also have questionable safety levels and side effects. In light of this, several experimental vaccines are in development in order to improve safety, reproducibility, and protective immune response against the etiologic agent of CLA, Corynebacterium pseudotuberculosis. In this review, we discussed aspects as antigen, adjuvant, routes of administration, protection level, and animal models used in CLA vaccine development, as well the challenges and future perspectives. KEY POINTS: Caseous lymphadenitis (CLA) does not have an appropriate commercial vaccine. Different experimental vaccines are in development aiming to protect against Corynebacterium pseudotuberculosis. An ideal vaccine for CLA is necessary for the disease control.
干酪性淋巴结炎（CLA）是一种传染性慢性疾病，在世界范围内给绵羊和山羊养殖造成了经济损失。CLA 目前没有有效的治疗方法，疫苗接种计划被证明是最好的控制策略。尽管已经有一些商业疫苗可用，但它们都不能提供完全的保护，其在绵羊和山羊中的效果有时并不理想，而且效率也不相同。它们的安全性和副作用也存在争议。有鉴于此，为了提高针对 CLA 的病原体——假结核棒状杆菌的安全性、重现性和保护性免疫反应，正在开发几种实验性疫苗。在本文中，我们讨论了 CLA 疫苗开发中使用的抗原、佐剂、给药途径、保护水平和动物模型等方面，以及面临的挑战和未来展望。
CLA 没有合适的商业疫苗。
正在开发针对假结核棒状杆菌的不同实验性疫苗，以提供保护。
控制 CLA 需要一种理想的疫苗。
